Higo Shuichiro
Department of Medical Therapeutics for Heart Failure, Osaka University Graduate School of Medicine, Suita 565-0871, Japan.
World J Stem Cells. 2023 Mar 26;15(3):71-82. doi: 10.4252/wjsc.v15.i3.71.
Cardiomyopathy is a pathological condition characterized by cardiac pump failure due to myocardial dysfunction and the major cause of advanced heart failure requiring heart transplantation. Although optimized medical therapies have been developed for heart failure during the last few decades, some patients with cardiomyopathy exhibit advanced heart failure and are refractory to medical therapies. Desmosome, which is a dynamic cell-to-cell junctional component, maintains the structural integrity of heart tissues. Genetic mutations in desmosomal genes cause arrhythmogenic cardiomyopathy (AC), a rare inheritable disease, and predispose patients to sudden cardiac death and heart failure. Recent advances in sequencing technologies have elucidated the genetic basis of cardiomyopathies and revealed that desmosome-related cardiomyopathy is concealed in broad cardiomyopathies. Among desmosomal genes, mutations in (which encodes PKP2) are most frequently identified in patients with AC. deficiency causes various pathological cardiac phenotypes. Human cardiomyocytes differentiated from patient-derived induced pluripotent stem cells (iPSCs) in combination with genome editing, which allows the precise arrangement of the targeted genome, are powerful experimental tools for studying disease. This review summarizes the current issues associated with practical medicine for advanced heart failure and the recent advances in disease modeling using iPSC-derived cardiomyocytes targeting desmosome-related cardiomyopathy caused by deficiency.
心肌病是一种以心肌功能障碍导致心脏泵衰竭为特征的病理状态,是晚期心力衰竭需要心脏移植的主要原因。尽管在过去几十年中已经开发出针对心力衰竭的优化药物治疗方法,但一些心肌病患者仍表现出晚期心力衰竭且对药物治疗无效。桥粒是一种动态的细胞间连接成分,维持心脏组织的结构完整性。桥粒基因的基因突变会导致致心律失常性心肌病(AC),这是一种罕见的遗传性疾病,使患者易发生心源性猝死和心力衰竭。测序技术的最新进展阐明了心肌病的遗传基础,并揭示桥粒相关心肌病隐藏在广泛的心肌病中。在桥粒基因中,编码PKP2的基因突变在AC患者中最常被发现。PKP2缺乏会导致各种病理性心脏表型。从患者来源的诱导多能干细胞(iPSC)分化而来的人类心肌细胞与基因组编辑相结合,能够精确排列靶向基因组,是研究疾病的强大实验工具。本综述总结了晚期心力衰竭实用医学的当前问题以及使用iPSC衍生的心肌细胞针对PKP2缺乏引起的桥粒相关心肌病进行疾病建模的最新进展。